Clomiphene Citrate Effectively Increases Testosterone in Obese, Young, Hypogonadal Men

Document Type


Publication Date



Background—Obesity has been associated with low testosterone (T) in adult males and in pubertal boys. Therapy for hypogonadism with exogenous T may lead to testicular atrophy and later infertility. Only a few studies have demonstrated that the Selective Estrogen Receptor Modulator (SERM) clomiphene citrate (CC), an estrogen receptor antagonist, increases T in obese hypogonadal men while preventing testicular atrophy. No studies to date using CC have been done in younger obese post-pubertal hypogonadal males. Objective—To determine whether CC therapy is effective in increasing serum T levels in hypogonadal post-pubertal obese males 18-21 years. Materials and Methods—A retrospective chart analysis of records in obese men aged 18-21 years was done. Patients with early morning T level